Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

Panitumumab 1PLX8394 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × IFL protocol × Head & Neck × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡